环丙沙星与氟康唑联合治疗期间QTc延长的发生率及相关危险因素
前瞻性观察研究纳入170例接受环丙沙星与氟康唑联合治疗的患者,其中149例(87.6%)为血液系统恶性肿瘤。QTc延长发生率为4.7%,未发现相关危险因素;联合治疗期间QTc间期平均延长10.7 ms(95%CI 7.2–14.1 ms)。鉴于发生率低,应重新考虑常规心电图监测。
要点
- 环丙沙星与氟康唑联合治疗期间QTc延长发生率为4.7%。
- 联合治疗期间QTc间期平均延长10.7 ms(95%CI 7.2–14.1 ms)。
- 未发现与QTc延长相关的危险因素,常规心电图监测可重新考虑。
核心结论
- 环丙沙星与氟康唑联合治疗患者QTc延长发生率为4.7%,低于一般人群的5%–11%。
- 未发现与QTc延长相关的危险因素。
- 鉴于发生率低,应重新考虑对该联合治疗患者进行常规心电图监测。
研究设计与样本
- 前瞻性观察研究,在Erasmus大学医学中心纳入接受环丙沙星与氟康唑联合治疗的住院患者170例。
- 其中149例(87.6%)因血液系统恶性肿瘤接受治疗。
- 在最后加用药物估计达峰浓度时间(Tmax)记录12导联心电图。
主要发现
- QTc延长发生率为4.7%。
- 联合治疗期间QTc间期平均延长10.7 ms(95%CI 7.2–14.1 ms)。
- 未发现患者特征、电解质、剂量、肝肾功能、合并使用其他QTc延长药物或CYP3A4抑制剂与QTc延长相关。
临床怎么用
- 对于接受环丙沙星与氟康唑联合治疗的患者,常规心电图监测的必要性可重新评估。
- 尽管QTc延长发生率低,仍需关注个体患者风险,但本研究未识别出特定危险因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM(S): Ciprofloxacin and fluconazole combination therapy is frequently used as prophylaxis for, and treatment of, infections in patients with haematological malignancies. However, both drugs are known to prolong the heart rate-corrected QT (QTc) interval, which is a serious risk factor for torsade de pointes (TdP). Therefore, the aim of the current study was to assess the prevalence of QTc prolongation during ciprofloxacin and fluconazole use. The secondary objective was to determine associated risk factors of QTc prolongation in these patients. METHODS: A prospective observational study was performed in patients admitted to the Erasmus University Medical Centre and treated with ciprofloxacin and fluconazole. A 12-lead electrocardiogram (ECG) was recorded at the estimated time to peak concentration (Tmax ) for the last added drug. The main outcome was the proportion of patients with QTc prolongation during treatment. Data on the following potential risk factors were collected: patient characteristics, serum electrolyte levels, dosage of ciprofloxacin and fluconazole, renal and liver function and concomitant use of other QTc-prolonging drugs and cytochrome P450 3A4 inhibitors. RESULTS: A total of 170 patients were included, of whom 149 (87.6%) were treated for haematological malignancies. The prevalence of QTc prolongation was 4.7%. No risk factors were found to be associated with QTc prolongation. The QTc interval increased by 10.7 ms [95% confidence interval (CI) 7.2, 14.1 ms] during ciprofloxacin and fluconazole combination therapy. CONCLUSION: The prevalence of QTc prolongation in patients using ciprofloxacin and fluconazole is low compared with the prevalence in the general population, which varies from 5% to 11%. In addition, no risk factors were found. Given the low prevalence, routine ECG monitoring in patients on this therapy should be reconsidered.
引用
- Berger FA, Monadian N, de Groot NMS, et al. QTc prolongation during ciprofloxacin and fluconazole combination therapy: prevalence and associated risk factors. Br J Clin Pharmacol. 2017. PMID: 29057492. doi:10.1111/bcp.13457
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。